SS-31 Research: Overview, Mechanism & Mitochondrial Function

SS-31, also known by its alias Elamipretide, is a fascinating mitochondria-targeted tetrapeptide that has garnered significant attention in cellular aging research and mitochondrial bioenergetics studies. Its unique structure facilitates its direct interaction with cardiolipin within the inner mitochondrial membrane, positioning it as a potent tool for investigating mitochondrial function, redox balance, and cellular energy metabolism.

Research surrounding SS-31 spans a broad spectrum of preclinical models, focusing on its intricate mechanisms of action related to mitochondrial integrity and efficiency. The scientific community’s interest is underscored by the current count of 122 indexed publications on PubMed and 1 registered study on ClinicalTrials.gov, highlighting its ongoing exploration as a research compound in various biological contexts.

SS-31 (Elamipretide): A Mitochondria-Targeted Tetrapeptide Overview

SS-31, also known by its alias Elamipretide, stands as a prominent mitochondria-targeted peptide of significant interest within the cellular aging and mitochondrial research communities. Classified specifically as a mitochondrial-targeted peptide, SS-31 represents a unique class of compounds designed to selectively interact with mitochondria, the essential organelles responsible for cellular energy production and metabolic regulation. Its mechanism of action is primarily understood through extensive studies focusing on its interaction with cardiolipin within the inner mitochondrial membrane and its profound impact on mitochondrial bioenergetics. This selective targeting and mechanism make SS-31 an invaluable research tool for elucidating fundamental aspects of mitochondrial physiology and pathology across various research peptides studies.

The research landscape surrounding SS-31 is robust and continually expanding, underscoring its relevance as a subject of intense scientific inquiry. To date, SS-31 has been featured in 122 publications indexed on PubMed, reflecting a substantial body of preclinical research exploring its effects in diverse biological systems and disease models. These studies span areas such as mitochondrial dysfunction, oxidative stress, and the maintenance of mitochondrial quality control. Furthermore, the translational potential of SS-31 has been acknowledged with one registered study on ClinicalTrials.gov, indicating a move towards investigating its biological activities in more complex research contexts. This dual emphasis on foundational mechanistic research and advanced translational exploration positions SS-31 as a critical compound for advancing our understanding of mitochondrial health and its implications for aging and chronic conditions.

As a mitochondria-targeted tetrapeptide, SS-31 offers researchers a unique lens through which to investigate the intricate processes governing mitochondrial function. Its relatively small size and specific molecular properties allow for targeted modulation of mitochondrial processes, distinguishing it from broader antioxidants or metabolic modulators. The ongoing research with SS-31 aims to unravel the precise molecular pathways influenced by its mitochondrial localization, particularly its role in modulating ATP production, reactive oxygen species (ROS) levels, and the overall efficiency of the electron transport chain. Understanding these intricate interactions is crucial for developing novel research strategies to address mitochondrial dysfunction in various experimental models.

Understanding the Chemical Structure and Properties of SS-31

SS-31, a synthetic tetrapeptide, possesses a specific chemical structure that is central to its remarkable ability to target and interact with mitochondria. As its name implies, it is composed of four amino acid residues. Crucially, the peptide incorporates specific D-amino acids and unique aromatic residues that confer its distinctive physiochemical characteristics. These structural features are not arbitrary; they are meticulously designed to facilitate its selective accumulation within mitochondria, bypassing the less specific targeting mechanisms of many conventional compounds. The precise arrangement and composition of these amino acids contribute to its amphipathic nature and positive charge, both of which are critical for its mitochondrial localization and function.

The intrinsic properties of SS-31, stemming from its molecular architecture, dictate its behavior in biological systems and its utility in research. Researchers utilize these properties to design experiments that effectively probe mitochondrial dynamics and bioenergetics. Key physicochemical characteristics include its molecular weight, net charge, and lipophilicity, which together influence its cell permeability, distribution, and stability. The peptide’s positive charge at physiological pH is particularly vital, enabling its electrophoretic accumulation across the highly negatively charged inner mitochondrial membrane, a fundamental principle of its targeting mechanism. Its amphipathic character, possessing both hydrophilic and hydrophobic regions, further supports its integration into and interaction with lipid bilayers, specifically the inner mitochondrial membrane rich in cardiolipin.

Key Physicochemical Properties of SS-31 Relevant to Research

Peptide Length: A tetrapeptide, meaning it consists of four amino acid residues. This small size contributes to its cell permeability.
Charge: Positively charged at physiological pH, a critical factor for its mitochondrial electrophoretic accumulation.
Amphipathicity: Possesses both hydrophobic and hydrophilic regions, enabling its interaction with lipid membranes and facilitating membrane penetration.
Stability: Engineered with D-amino acids to enhance resistance to enzymatic degradation, providing increased stability in research settings and biological matrices.
Mitochondrial Membrane Permeability: Readily permeates cellular and mitochondrial membranes due to its favorable physicochemical properties, ensuring effective intracellular delivery to the target organelle.
Cardiolipin Binding Affinity: Exhibits high binding affinity for cardiolipin, a unique phospholipid found almost exclusively in the inner mitochondrial membrane, which is integral to its mechanism of action.

Understanding these fundamental structural and physicochemical properties is paramount for researchers when designing experiments involving SS-31. Factors such as purity, stability, and formulation can significantly influence experimental outcomes. Royal Peptide Labs provides Certificate of Analysis (CoA) for its research peptides, ensuring researchers have access to critical data on the quality and integrity of the compound for robust and reproducible studies.

Mechanisms of Mitochondrial Targeting: How SS-31 Localizes

The specificity with which SS-31 localizes to mitochondria is a cornerstone of its research utility and a key area of investigation. Unlike classical protein import pathways that involve complex receptor-mediated processes, SS-31’s mitochondrial targeting is primarily driven by physicochemical principles. The prevailing mechanism centers on its positive charge and the substantial negative electrochemical potential that exists across the inner mitochondrial membrane. This potential, typically ranging from -150 to -180 mV (matrix negative), acts as an electrophoretic force, drawing the positively charged SS-31 molecules into the mitochondrial matrix and intermembrane space. This passive accumulation mechanism is efficient and highly selective for mitochondria within living cells, making SS-31 a valuable probe for studying mitochondrial health without the complexities of genetic manipulation or viral delivery systems.

Beyond simple electrophoretic accumulation, the interaction of SS-31 with cardiolipin plays a pivotal role in its mitochondrial localization and subsequent biological effects. Cardiolipin is a unique, double-chained phospholipid found almost exclusively in the inner mitochondrial membrane, where it is essential for the structure and function of respiratory enzyme complexes. SS-31 exhibits a high affinity for cardiolipin, forming stable complexes that anchor the peptide to the inner mitochondrial membrane. This interaction is not merely a passive binding; it is thought to re-orient SS-31 within the membrane, facilitating its functional engagement with critical mitochondrial processes. Research has shown that disruption of cardiolipin structure or content can significantly alter SS-31’s efficacy, highlighting the indispensability of this lipid for the peptide’s mechanism of action.

The specific structural features of SS-31, including its amphipathic nature and the presence of aromatic residues, further optimize its interaction with the hydrophobic core of the mitochondrial membrane while maintaining solubility in aqueous environments. This balanced hydrophobicity and hydrophilicity allow the peptide to traverse cellular membranes efficiently and integrate into the lipid environment of the mitochondria. The robust and selective targeting mechanism of SS-31 to mitochondria provides a critical advantage for researchers. It ensures that observed effects are localized to the organelle, allowing for precise investigations into mitochondrial-specific pathways without confounding extra-mitochondrial influences. This precision is invaluable when exploring its impact on bioenergetics, oxidative stress, and mitochondrial dynamics, forming a foundation for understanding its potential as a research agent in a wide array of experimental models.

The Role of Cardiolipin Binding in SS-31’s Mechanism of Action

Cardiolipin, a unique anionic phospholipid, is predominantly localized to the inner mitochondrial membrane (IMM) and plays a pivotal role in maintaining mitochondrial structure and function. Its distinctive dimeric structure and multiple unsaturated fatty acyl chains are crucial for stabilizing membrane curvature, facilitating protein supercomplex formation within the electron transport chain (ETC), and supporting critical enzymatic activities. Research indicates that the integrity and proper localization of cardiolipin are fundamental for efficient oxidative phosphorylation and overall mitochondrial bioenergetics. Disruptions in cardiolipin structure or content are often associated with various mitochondrial dysfunctions and cellular stress states, making it a key target for research into mitochondrial support.

SS-31 (Elamipretide) is a mitochondria-targeted tetrapeptide whose mechanism of action is significantly predicated on its specific interaction with cardiolipin. This interaction is primarily driven by both electrostatic and hydrophobic forces. The positively charged residues within SS-31 are attracted to the negatively charged head groups of cardiolipin, while its lipophilic components facilitate insertion into the membrane environment. This binding is considered crucial for SS-31’s mitochondrial localization and its subsequent effects. By selectively associating with cardiolipin, SS-31 is hypothesized to help restore or stabilize the optimal conformation of the IMM, which is essential for the efficient function of membrane-bound protein complexes, including those involved in the ETC.

Studies investigating SS-31’s interaction with cardiolipin suggest that this binding may protect cardiolipin from oxidative damage and prevent its peroxidation, a process that can lead to membrane destabilization and mitochondrial dysfunction. Oxidized cardiolipin can impair the function of ETC complexes, alter membrane fluidity, and contribute to the release of pro-apoptotic factors. By associating with cardiolipin, SS-31 may help to maintain the phospholipid’s structural integrity and its proper interaction with key mitochondrial proteins, thereby preserving critical functions such as proton gradient formation and ATP synthesis. This selective targeting via cardiolipin binding positions SS-31 as a compound of significant interest for researchers exploring mitochondrial membrane health and function.

Further exploration into the intricacies of SS-31’s cardiolipin binding properties is ongoing in the research community. Understanding the precise stoichiometry and kinetics of this interaction, as well as the downstream conformational changes induced in the IMM, remains a priority for elucidating its full mechanistic profile. The cardiolipin interaction is recognized as a cornerstone of SS-31’s activity, enabling it to exert its modulatory effects on various aspects of mitochondrial physiology. For a broader perspective on the specific molecular pathways implicated, researchers may refer to our SS-31 Mechanism of Action page.

SS-31 and Mitochondrial Bioenergetics: Modulating ATP Production

Mitochondrial bioenergetics encompasses the intricate processes by which cells generate and utilize energy, primarily in the form of adenosine triphosphate (ATP). This involves the careful orchestration of nutrient metabolism, the electron transport chain (ETC), and oxidative phosphorylation (OXPHOS). Optimal mitochondrial function is synonymous with efficient ATP production, which is vital for virtually all cellular processes, from maintaining ion gradients to powering molecular synthesis and mechanical work. Dysregulation in bioenergetic pathways is a hallmark of numerous cellular stress states and has been a central focus of research into aging and various disease models.

Research suggests that SS-31 (Elamipretide) exerts modulatory effects on mitochondrial bioenergetics, primarily by enhancing the efficiency of ATP production. This enhancement is theorized to stem from its direct interaction with cardiolipin, as discussed previously, which helps to stabilize the inner mitochondrial membrane (IMM) and optimize the environment for the ETC complexes. By preserving the structural and functional integrity of the IMM, SS-31 may contribute to maintaining a robust mitochondrial membrane potential (ΔΨm). A stable ΔΨm is critical for driving the ATP synthase enzyme (Complex V) to produce ATP from ADP and inorganic phosphate, forming the final step in oxidative phosphorylation.

The observed impact of SS-31 on ATP production is often assessed in research settings by measuring various bioenergetic parameters. These include cellular ATP levels, oxygen consumption rates (OCR), extracellular acidification rates (ECAR), and direct assessments of mitochondrial membrane potential. Studies have indicated that SS-31 may help to restore compromised ATP synthesis in models of mitochondrial dysfunction, potentially by optimizing electron flow through the ETC and reducing proton leak across the IMM. This can lead to a more efficient coupling of oxygen consumption to ATP generation, thereby improving overall bioenergetic capacity within the cell.

Investigating the precise mechanisms through which SS-31 modulates ATP production involves detailed analysis of its effects on specific ETC complexes, proton motive force, and the activity of ATP synthase itself. These studies often employ high-resolution respirometry and fluorometric probes to monitor mitochondrial function in real-time within isolated mitochondria, permeabilized cells, or intact cellular systems. The consistent finding that SS-31 is studied in bioenergetics research underscores its relevance as a tool for probing and potentially influencing cellular energy metabolism, offering avenues for exploring its utility in contexts where mitochondrial energy deficits are implicated.

Impact on Mitochondrial Respiration and Electron Transport Chain Function

Mitochondrial respiration, the process by which cells consume oxygen to generate energy, is intricately linked to the electron transport chain (ETC). This chain, comprised of four major protein complexes (Complexes I-IV) and two mobile electron carriers (ubiquinone and cytochrome c), establishes a proton gradient across the inner mitochondrial membrane (IMM). This gradient, known as the proton motive force, is then utilized by ATP synthase (Complex V) to produce ATP. The efficiency and integrity of the ETC are paramount for cellular health, and dysfunctions in any part of this system can lead to impaired ATP production, increased reactive oxygen species (ROS) generation, and cellular stress.

SS-31 (Elamipretide) is hypothesized to modulate mitochondrial respiration and ETC function, primarily through its interaction with cardiolipin within the IMM. By stabilizing the IMM and potentially restoring the optimal lipid environment, SS-31 may facilitate the proper assembly and functional integrity of the ETC supercomplexes. These supercomplexes, formed by the association of individual ETC complexes, are thought to enhance electron transfer efficiency and minimize electron leakage, thereby reducing the generation of damaging free radicals. Research suggests that SS-31 can improve the catalytic activity of specific ETC complexes, particularly Complex I and Complex IV, which are often targets of oxidative damage and dysfunction.

The impact of SS-31 on ETC function can be quantitatively assessed through various research methodologies, including measurements of oxygen consumption rates (OCR) using high-resolution respirometry, specific activity assays for individual ETC complexes, and analysis of mitochondrial membrane potential. Enhanced OCR, particularly through Complex I and Complex II substrates, can indicate improved electron flow. Furthermore, a stable mitochondrial membrane potential (ΔΨm) is a direct reflection of efficient proton pumping by the ETC. Studies have indicated that SS-31 may help to maintain or restore ΔΨm under conditions of mitochondrial stress, suggesting a beneficial influence on the efficiency of the ETC.

The table below summarizes the primary ETC complexes and how SS-31’s proposed mechanism via cardiolipin interaction might influence their function, contributing to improved mitochondrial respiration:

ETC Complex	Primary Function	Proposed SS-31 Influence
Complex I (NADH Dehydrogenase)	Oxidizes NADH, pumps protons across IMM	Stabilizes conformation via cardiolipin, potentially enhancing electron transfer efficiency and reducing ROS generation.
Complex II (Succinate Dehydrogenase)	Oxidizes FADH₂ from the Krebs cycle, transfers electrons to ubiquinone.	Indirect support through IMM stabilization; less direct interaction than Complex I or IV, but benefits from overall membrane health.
Complex III (Cytochrome c Reductase)	Transfers electrons from ubiquinol to cytochrome c, pumps protons.	Maintains optimal IMM environment for supercomplex formation with other ETC complexes, aiding efficient electron flow.
Complex IV (Cytochrome c Oxidase)	Reduces oxygen to water, pumps protons.	May directly enhance activity or stabilize interaction with cardiolipin, critical for its function and the final steps of proton pumping.
Complex V (ATP Synthase)	Utilizes proton gradient to synthesize ATP.	Benefits from enhanced proton motive force due to more efficient ETC function and a stable IMM environment.

By impacting these critical components of the electron transport chain, SS-31 is positioned as a valuable research tool for understanding and modulating mitochondrial respiratory dynamics in various experimental models.

Modulation of Reactive Oxygen Species (ROS) and Oxidative Stress Pathways

Mitochondria, while essential for cellular energy production, are also a primary intracellular source of reactive oxygen species (ROS). During the normal process of oxidative phosphorylation, a small percentage of electrons can prematurely reduce molecular oxygen, generating superoxide radicals (O₂^•−), which are then converted to other ROS like hydrogen peroxide (H₂O₂). While low levels of ROS can act as signaling molecules, an imbalance between ROS production and antioxidant defense mechanisms leads to oxidative stress. This state is highly detrimental, causing damage to mitochondrial components such (DNA, proteins, lipids, particularly cardiolipin) and contributing significantly to cellular dysfunction, aging phenotypes, and various age-related pathologies observed in research models.

SS-31, as a mitochondria-targeted tetrapeptide, has been extensively studied for its ability to modulate mitochondrial ROS levels. Its unique amphipathic structure enables it to selectively target the inner mitochondrial membrane, where it interacts with cardiolipin. By binding to cardiolipin, SS-31 is hypothesized to stabilize the inner mitochondrial membrane and optimize the function of the electron transport chain (ETC). This stabilization may contribute to reducing electron leakage from ETC complexes, particularly Complex I and Complex III, which are known hot spots for superoxide generation. Consequently, SS-31’s impact on cardiolipin structure and ETC efficiency can lead to a direct reduction in the production of mitochondrial ROS, thereby mitigating the onset of oxidative stress within the cell.

Research into SS-31’s role in oxidative stress pathways often involves a multi-faceted approach. Investigators frequently employ fluorescent probes like MitoSOX Red for superoxide detection or Dihydroethidium (DHE) to quantify intracellular ROS. Markers of oxidative damage, such as lipid peroxidation (e.g., malondialdehyde, 4-hydroxynonenal), protein carbonylation, and oxidized DNA bases (e.g., 8-hydroxy-2′-deoxyguanosine), are crucial for assessing the downstream consequences of oxidative stress. Furthermore, studying the activity and expression of antioxidant enzymes, including superoxide dismutases (SODs), catalase, and glutathione peroxidases, provides insight into the cellular antioxidant response in the presence of SS-31. The consistent observation across numerous studies points towards SS-31’s capacity to restore mitochondrial redox homeostasis, offering a valuable research tool for understanding and addressing mitochondrial oxidative stress.

SS-31’s Influence on Mitochondrial Dynamics and Quality Control

Mitochondrial health is not solely dependent on optimal bioenergetics and reduced oxidative stress; it is also intricately linked to dynamic processes of fission and fusion, collectively known as mitochondrial dynamics, and critical quality control mechanisms such as mitophagy and biogenesis. Mitochondrial dynamics ensure a functional and adaptable mitochondrial network, allowing mitochondria to fuse to exchange contents and buffer damage, or to divide (fission) to isolate damaged portions or facilitate their distribution. Mitochondrial quality control pathways, including the selective degradation of damaged mitochondria via mitophagy and the generation of new mitochondria through biogenesis, are essential for maintaining a healthy mitochondrial population and preventing the accumulation of dysfunctional organelles, which is a hallmark of cellular aging.

SS-31’s reported ability to improve mitochondrial bioenergetics and reduce ROS production suggests a potential indirect, and possibly direct, influence on these dynamic and quality control pathways. A healthier, more energized mitochondrial network, characterized by robust ATP production and minimal oxidative damage, is inherently less likely to trigger excessive fission or mitophagy signals. By preserving cardiolipin integrity and enhancing ETC efficiency (for a deeper dive into the broader mechanisms of SS-31, please refer to our SS-31 Mechanism of Action page), SS-31 may contribute to maintaining the mitochondrial membrane potential and reducing the cellular stress that often drives dysfunctional dynamics. Research indicates that interventions that support mitochondrial function can shift the balance towards fusion and attenuated mitophagy in situations where it would otherwise be excessively activated, thus promoting overall mitochondrial network integrity.

Investigating SS-31’s effects on mitochondrial dynamics and quality control involves a combination of molecular and imaging techniques. Live-cell microscopy and immunofluorescence imaging are critical for observing mitochondrial morphology, network connectivity, and the localization of key proteins involved in fission (e.g., Drp1), fusion (e.g., Mfn1/2, OPA1), and mitophagy (e.g., PINK1, Parkin, LC3B). Quantitative PCR and Western blot analyses are used to assess the expression levels of genes and proteins associated with these processes. Furthermore, functional assays measuring mitochondrial biogenesis (e.g., assessment of mitochondrial DNA copy number or expression of PGC-1α) and mitophagy flux (e.g., using tandem fluorescent reporters like mCherry-GFP-LC3) provide comprehensive insights into how SS-31 may modulate the delicate balance of mitochondrial network maintenance.

Investigating the Mitochondrial Permeability Transition Pore (mPTP) Interaction

The mitochondrial permeability transition pore (mPTP) is a non-specific channel that forms in the inner mitochondrial membrane, typically under conditions of cellular stress. Its opening leads to a sudden increase in the permeability of the inner mitochondrial membrane to solutes up to ~1.5 kDa, causing mitochondrial swelling, depolarization, cessation of ATP synthesis, and rupture of the outer mitochondrial membrane. This, in turn, can result in the release of pro-apoptotic factors into the cytosol, committing the cell to programmed cell death. The triggers for mPTP opening are numerous, including high matrix calcium concentrations, oxidative stress, inorganic phosphate, and depletion of adenine nucleotides. Dysregulation of mPTP activity is implicated in a wide array of pathological conditions, from ischemia-reperfusion injury and neurodegeneration to various forms of cellular aging and tissue damage.

Given SS-31’s established role in targeting mitochondria, improving bioenergetics, and mitigating oxidative stress, its potential interaction with the mPTP is a significant area of research interest. By stabilizing the inner mitochondrial membrane through its interaction with cardiolipin, and by reducing the very stressors (high ROS, impaired bioenergetics) that promote mPTP opening, SS-31 is hypothesized to raise the threshold for mPTP induction. This protective effect could be crucial in cellular models of stress and injury, where preventing premature mPTP opening is vital for cell survival. The mechanism could involve direct stabilization of the inner membrane, rendering the mPTP less sensitive to its typical triggers, or indirect effects by maintaining mitochondrial health and function, thereby reducing the cellular signals that would otherwise promote pore opening.

Researching SS-31’s influence on mPTP activity requires specific experimental methodologies designed to assess pore dynamics. Key assays include:

Calcium Retention Capacity (CRC) Assay: This is a primary method for assessing mPTP sensitivity. Isolated mitochondria are exposed to repeated pulses of calcium, and the time or amount of calcium required to induce mPTP opening (indicated by mitochondrial swelling or release of a fluorescent calcium indicator) is measured. A higher CRC suggests resistance to mPTP opening.
Mitochondrial Swelling Assay: Based on the decrease in optical density (absorbance at 540 nm) as mitochondria swell due to mPTP opening in a hypotonic medium.
Membrane Potential Measurement: Dyes like JC-1 or TMRM are used to monitor the inner mitochondrial membrane potential (ΔΨm). mPTP opening leads to rapid depolarization, detectable as a loss of fluorescence.
ATP/ADP Translocase (ANT) Studies: While the exact composition of the mPTP remains debated, components like ANT are often implicated. Researchers may investigate SS-31’s interaction with ANT or other potential mPTP constituents.

Understanding how SS-31 modulates mPTP activity offers critical insights into its protective effects against various forms of mitochondrial dysfunction and cellular demise, furthering our understanding of its therapeutic potential in research models.

Preclinical Research Models and Methodologies for SS-31 Studies

The investigation of SS-31 (Elamipretide) as a mitochondrial-targeted peptide necessitates a diverse array of preclinical research models and sophisticated methodologies. These approaches are fundamental for elucidating its mechanism of action, assessing its impact on mitochondrial function, and identifying potential areas of research interest. The selection of appropriate models, ranging from isolated mitochondria to complex *in vivo* systems, is critical for addressing specific research questions regarding SS-31’s interaction with cellular bioenergetics and its broader physiological effects.

In Vitro Model Systems and Assays

In vitro studies form the bedrock of SS-31 research, providing controlled environments to analyze direct cellular and mitochondrial responses. Researchers frequently utilize a variety of cell lines, including human and rodent origin, which can be engineered to mimic specific conditions of mitochondrial dysfunction, such as oxidative stress, nutrient deprivation, or exposure to toxins. Primary cell cultures, derived from specific tissues like cardiomyocytes, neurons, or kidney cells, offer a more physiologically relevant context. Key methodologies employed include:

Mitochondrial Bioenergetics: Assays like the Seahorse XF Analyzer are used to measure oxygen consumption rate (OCR) and extracellular acidification rate (ECAR), providing insights into mitochondrial respiration, ATP production, and glycolytic flux.
Reactive Oxygen Species (ROS) Measurement: Fluorescent probes (e.g., MitoSOX Red for mitochondrial superoxide) and flow cytometry or microscopy quantify ROS levels, indicating oxidative stress modulation.
Mitochondrial Membrane Potential (ΔΨm) Assays: Dyes such as JC-1 or TMRM evaluate mitochondrial membrane integrity and potential, critical indicators of mitochondrial health.
Mitochondrial Morphology and Dynamics: Live-cell imaging and electron microscopy assess mitochondrial fusion, fission, and overall network integrity, revealing SS-31’s influence on mitochondrial quality control.
Cardiolipin Analysis: Mass spectrometry and specific staining techniques are used to investigate SS-31’s binding to cardiolipin and its effects on cardiolipin composition and organization within the inner mitochondrial membrane.

In Vivo Animal Models and Outcome Measures

To understand the systemic implications of SS-31, research often progresses to *in vivo* animal models. Rodent models, particularly mice and rats, are predominant due to their genetic manipulability and cost-effectiveness. These models are employed to simulate various conditions associated with mitochondrial dysfunction, including models of aging, ischemia-reperfusion injury (e.g., cardiac, renal, cerebral), neurodegenerative conditions, metabolic disorders, and muscle wasting. SS-31 is typically administered via injection (e.g., subcutaneous, intravenous, intraperitoneal), and researchers carefully establish dose-response curves and time-course analyses.

End-point analyses in *in vivo* studies encompass a broad range of physiological and biochemical assessments. These include:

Organ Function Assessment: Physiological readouts such as cardiac ejection fraction, glomerular filtration rate, motor coordination tests, and cognitive function evaluations.
Histopathology and Immunohistochemistry: Tissue samples are examined for cellular damage, inflammation, fibrosis, and specific protein expression markers related to mitochondrial function and oxidative stress.
Mitochondrial Isolation and Biochemical Assays: Mitochondria isolated from specific organs can be subjected to *in vitro* bioenergetic assays, enzymatic activity measurements, and Western blotting for mitochondrial protein analysis.
Biomarker Analysis: Blood or urine samples are analyzed for systemic markers of oxidative stress, inflammation, and cellular injury.

Ensuring the quality and consistency of SS-31 is paramount for reliable preclinical research. Researchers are encouraged to consult resources like our Certificate of Analysis to verify the purity and authenticity of the peptide used in their studies, as variations can significantly impact experimental outcomes.

Key Findings from In Vitro and In Vivo Research with SS-31

The extensive body of research on SS-31, encompassing over 122 indexed publications in PubMed, has illuminated its profound influence on mitochondrial health and function across a variety of experimental models. These studies consistently highlight SS-31’s ability to selectively target mitochondria and exert beneficial effects, primarily through its interaction with cardiolipin and subsequent modulation of bioenergetic processes. This research provides a foundation for understanding SS-31’s potential utility as a research tool in cellular aging and mitochondrial biology.

Impact on Mitochondrial Bioenergetics and Oxidative Stress

A central theme in SS-31 research is its capacity to enhance mitochondrial bioenergetics. In vitro studies have demonstrated that SS-31 can improve mitochondrial respiration efficiency, increase ATP production, and enhance the overall capacity of the electron transport chain, particularly under conditions of stress or dysfunction. This bioenergetic optimization is closely linked to its role in stabilizing cardiolipin, a phospholipid critical for maintaining the structural and functional integrity of the inner mitochondrial membrane. By preserving cardiolipin structure, SS-31 helps maintain the proper assembly and activity of respiratory supercomplexes.

Beyond bioenergetics, SS-31 has been widely shown to modulate reactive oxygen species (ROS) production and mitigate oxidative stress. Mitochondria are primary sites of ROS generation, and excessive ROS can lead to cellular damage. Research indicates that SS-31 can reduce the overproduction of superoxide and other ROS within mitochondria, thereby protecting cellular components from oxidative damage. This reduction in oxidative stress is thought to contribute to its observed protective effects in various models of cellular injury and aging.

Influence on Mitochondrial Dynamics and Quality Control

SS-31’s research extends to its role in mitochondrial dynamics and quality control, processes essential for maintaining a healthy mitochondrial network. Studies have explored how SS-31 influences the balance between mitochondrial fusion and fission, which are vital for adapting to metabolic demands and removing damaged mitochondria. While not a direct mediator of fusion or fission proteins, SS-31’s impact on cardiolipin stability and membrane integrity can indirectly support these processes, contributing to a more robust and functional mitochondrial population. Furthermore, its ability to mitigate stress can reduce the triggers for excessive fission or mitophagy, helping to preserve the mitochondrial pool.

The breadth of SS-31’s observed effects in preclinical research can be summarized by its impact on several key areas:

Research Area	Observed Effects of SS-31
Cardiovascular Models	Improved cardiac function post-ischemia-reperfusion, reduced infarct size, enhanced endothelial function, preservation of mitochondrial structure.
Renal Models	Protection against acute kidney injury, mitigation of chronic kidney disease progression, improved mitochondrial respiration in renal cells.
Neurodegenerative Models	Neuroprotection, reduction of oxidative stress in neuronal cells, preservation of synaptic function, modulation of neuroinflammation.
Metabolic Disorders	Improvements in insulin sensitivity, reduced mitochondrial dysfunction in obesity and diabetes models, enhanced metabolic flexibility.
Ocular Models	Protection of retinal ganglion cells, mitigation of mitochondrial dysfunction in conditions like glaucoma and age-related macular degeneration.
Skeletal Muscle Function	Improved exercise capacity, reduced muscle fatigue, preservation of mitochondrial content and function in aging muscle models.

These diverse findings underscore SS-31’s consistent ability to support mitochondrial integrity and function across a wide array of physiological systems and pathological conditions in *in vitro* and *in vivo* research settings, making it a valuable tool for researchers investigating mitochondrial mechanisms of cellular health and disease.

Translational Research Perspective: Analyzing the ClinicalTrials.gov Landscape

The journey from fundamental *in vitro* and *in vivo* preclinical research to understanding potential implications in human studies is a critical aspect of translational science. For SS-31, this perspective is anchored by the transparency offered by registries like ClinicalTrials.gov. This public database serves as a global resource for information on human research studies, providing details on study design, participant criteria, interventions, and measured outcomes. It is crucial to emphasize that inclusion in this registry denotes a study is underway or completed, but it does not equate to regulatory approval for any therapeutic use, nor does it imply that the investigational compound is generally safe or effective for human consumption.

Overview of the ClinicalTrials.gov Registry for SS-31

As per the provided data, SS-31 (Elamipretide) has one registered study on ClinicalTrials.gov. This singular registration indicates that, while preclinical research is extensive, the exploration of SS-31 in human research contexts has been limited to a specific investigational pathway. Typically, such studies are conducted under strict regulatory oversight and are designed to assess specific parameters within tightly controlled research settings, often focusing on safety endpoints, pharmacokinetics, and preliminary indicators of biological activity in well-defined research populations. The details of the registered study would provide researchers with context regarding the specific research questions being addressed, the types of participants being studied, and the primary and secondary outcomes being investigated, all within a research framework.

It is important for researchers to analyze the specific details of any registered study, including its phase, the conditions being investigated (e.g., specific mitochondrial dysfunction, organ system impairment), and the metrics used to evaluate the investigational compound. Such information can inform further preclinical research by identifying areas where SS-31’s mechanism or observed effects might be particularly relevant for investigation, or conversely, areas where more foundational preclinical work is still needed. This analytical approach helps refine hypotheses and guide the direction of future *in vitro* and *in vivo* experiments.

Implications for Future Preclinical Research

The existence of a registered study on ClinicalTrials.gov, even if it is a single instance, provides a unique data point within the broader SS-31 research landscape. It bridges the gap between the vast body of preclinical evidence and the early stages of human research investigation. For cellular aging researchers, understanding the objectives and outcomes of such a study can help to prioritize research directions, potentially highlighting specific mitochondrial pathways or disease models that warrant deeper preclinical exploration. For instance, if a human study investigated markers related to cardiac mitochondrial function, it might encourage further detailed *in vitro* studies on SS-31’s effects on cardiomyocyte bioenergetics or *in vivo* studies in models of cardiac aging.

Ultimately, the translational research perspective for SS-31 reinforces its status as a compound under active scientific investigation. The data generated from human research studies, alongside the extensive preclinical work, contributes to a more comprehensive understanding of SS-31’s characteristics and potential as a research tool. Researchers interested in the broader context of research peptides and their investigational applications may find value in exploring resources such as What are Research Peptides? to further contextualize their work. This iterative process of preclinical and early human research continuously refines our scientific understanding, ensuring that SS-31 remains a valuable subject for advanced mitochondrial and cellular aging research.

Emerging Research Areas and Unanswered Questions for SS-31

As a prominent mitochondria-targeted tetrapeptide, SS-31 (Elamipretide) has garnered significant attention in bioenergetics and cardiolipin research, evidenced by over 122 PubMed publications. Despite the breadth of existing knowledge, several critical avenues for investigation remain underexplored, presenting fertile ground for future research. A deeper understanding of these areas is crucial for fully elucidating the peptide’s therapeutic potential in models of cellular aging and mitochondrial dysfunction.

One key area involves the intricate interplay between SS-31 and cellular processes beyond direct mitochondrial modulation. While its primary mechanism centers on cardiolipin binding and bioenergetic enhancement, researchers are beginning to explore its broader impact on other cellular organelles and signaling pathways. For instance, how does the preservation of mitochondrial integrity by SS-31 influence endoplasmic reticulum (ER) stress responses, particularly in conditions where mitochondrial and ER functions are tightly coupled? Furthermore, its potential role in lysosomal health and autophagy pathways, which are critical for cellular quality control, warrants detailed investigation. Understanding these systemic effects could reveal novel pathways by which SS-31 contributes to cellular resilience.

Tissue-Specific Responses and Delivery Optimization

The efficacy of SS-31 has been demonstrated across various preclinical models. However, a more comprehensive understanding of tissue-specific responses and optimal delivery strategies *in vivo* is still emerging. While the peptide is generally well-tolerated in research settings, variations in cellular uptake, metabolism, and persistence across different tissue types could significantly influence its functional outcomes. Future studies could focus on advanced imaging techniques to track SS-31 localization and accumulation in specific cell populations within complex organ systems. Furthermore, investigating novel delivery platforms that could enhance targeted mitochondrial accumulation in hard-to-reach tissues or cell types would be invaluable for optimizing research protocols and maximizing translational impact.

Long-Term Effects and Epigenetic Modulation

Most existing research on SS-31 has focused on acute or sub-acute interventions. A significant unanswered question pertains to the long-term effects of SS-31 administration on mitochondrial function, cellular aging hallmarks, and overall organismal health in aging models. Does chronic SS-31 exposure lead to sustained mitochondrial improvements, or are there adaptive responses that might alter its efficacy? Additionally, considering the profound influence of mitochondrial health on epigenetic modifications and gene expression, investigating whether SS-31 indirectly modulates nuclear epigenetics – such as DNA methylation or histone acetylation patterns – represents an exciting and largely unexplored frontier. Such research could uncover broader implications for cellular longevity and disease susceptibility.

Methodological Considerations for SS-31 Research Protocols

The robust study of SS-31, a mitochondrial-targeted tetrapeptide, demands rigorous methodological approaches to ensure accurate and reproducible results. Researchers must carefully consider several factors, from peptide quality and handling to appropriate experimental design and analytical techniques. Given its delicate nature and specific mechanism of action in cardiolipin and bioenergetics research, attention to detail in protocol development is paramount for generating meaningful data.

A fundamental starting point for any SS-31 investigation is the quality and purity of the research peptide. High-quality SS-31, characterized by a detailed Certificate of Analysis (CoA) verifying its identity, purity, and concentration, is essential. Impurities can introduce confounding variables, leading to misinterpretations of experimental outcomes. Researchers should always confirm the supplier’s commitment to quality testing to ensure the integrity of the compound. Furthermore, accurate reconstitution and preparation are critical. SS-31 is typically supplied as a lyophilized powder and should be reconstituted in an appropriate solvent, often sterile water or a physiological buffer, immediately prior to use or for aliquoting for storage. The chosen solvent and subsequent dilution steps must maintain peptide stability and prevent aggregation, which can diminish its biological activity.

Experimental Design and Controls

Careful experimental design is crucial for valid SS-31 research. This includes establishing appropriate concentration ranges for *in vitro* studies and dosing regimens for *in vivo* models, based on literature review and preliminary dose-response experiments. Due to SS-31’s mitochondrial targeting, studies should incorporate specific controls:

Vehicle Controls: Essential for both *in vitro* and *in vivo* studies to account for any effects of the solvent or administration method.
Scrambled Peptides: Non-functional peptide sequences with similar amino acid composition can serve as valuable negative controls, distinguishing specific SS-31 effects from general peptide-mediated interactions.
Positive Controls: Other known mitochondrial modulators or antioxidants can be used to validate assay performance and provide comparative benchmarks for SS-31’s efficacy.
Mitochondrial-Specific Inhibitors: Compounds that target specific components of the electron transport chain or mitochondrial processes can help dissect the precise pathways influenced by SS-31.

When assessing mitochondrial function, a comprehensive panel of assays is recommended. These include, but are not limited to, measurements of oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) using Seahorse XF analyzers to assess mitochondrial respiration and glycolysis, respectively. ATP production assays, mitochondrial membrane potential (ΔΨm) assessments using fluorescent dyes, and quantification of reactive oxygen species (ROS) are also critical. Beyond bioenergetics, researchers should consider evaluating mitochondrial dynamics (fission/fusion), morphology, and the integrity of the mitochondrial permeability transition pore (mPTP) to gain a holistic understanding of SS-31’s impact.

Storage, Handling, and Stability for Laboratory Research Use

Maintaining the integrity and activity of SS-31 (Elamipretide) is paramount for the reliability and reproducibility of research findings. As a delicate peptide, SS-31 is susceptible to degradation if not handled and stored correctly. Adherence to strict protocols for its storage, reconstitution, and handling is essential for preserving its mitochondrial-targeted properties and ensuring consistent experimental results in cardiolipin and bioenergetics research. For more detailed guidance, researchers are encouraged to consult specific SS-31 storage and handling information.

Lyophilized Powder Storage

Upon receipt, SS-31 is typically supplied as a lyophilized (freeze-dried) powder. In this form, it is relatively stable for extended periods. The recommended storage conditions for lyophilized SS-31 powder are at -20°C or colder. It should be stored in a tightly sealed container, protected from light and moisture. Exposure to elevated temperatures, humidity, or prolonged light can lead to degradation, rendering the peptide less effective or introducing impurities. Researchers should ensure that the product container is allowed to equilibrate to room temperature before opening to prevent condensation, which can introduce moisture.

Reconstitution and Solution Stability

Reconstitution is a critical step. SS-31 should be reconstituted in an appropriate solvent, such as sterile distilled water, physiological saline, or a suitable buffer (e.g., PBS) to achieve a stock solution. The specific concentration chosen for the stock solution will depend on the experimental design, but it is often recommended to create concentrated stock solutions to allow for subsequent dilutions. Once reconstituted, the peptide becomes more vulnerable to degradation. Key considerations for reconstituted solutions include:

Parameter	Recommendation
Storage Temperature	-20°C or -80°C for long-term storage. Avoid frequent freeze-thaw cycles.
Aliquoting	Divide stock solutions into single-use aliquots to minimize degradation from repeated thawing.
Solvent Compatibility	Ensure the chosen solvent is compatible with the peptide and the experimental system.
Light Protection	Store reconstituted solutions in amber vials or protect from light exposure.
pH Sensitivity	Maintain a physiological pH (typically pH 7.0-7.4) where possible, as extreme pH values can induce degradation.
Short-Term Storage	For use within 24-48 hours, solutions may be stored at 2-8°C, but -20°C or colder is preferable.

Repeated freezing and thawing cycles are highly detrimental to peptide stability and should be strictly avoided. Each freeze-thaw event can cause denaturation, aggregation, and loss of activity. Therefore, preparing appropriate aliquots is a recommended practice to preserve the research compound over its intended shelf life. Additionally, researchers should always handle SS-31 using sterile techniques to prevent microbial contamination, which can also contribute to peptide degradation.

Future Directions in SS-31 Mitochondrial Research

The extensive research surrounding SS-31 (Elamipretide), evidenced by over 120 indexed PubMed publications and one registered clinical study, has firmly established its role as a key mitochondrial-targeted peptide in bioenergetics and cardiolipin research. This foundational work has illuminated SS-31’s capacity to restore mitochondrial function, modulate reactive oxygen species, and influence mitochondrial dynamics across various preclinical models. However, the depth of its mechanisms and the breadth of its potential utility in diverse research contexts continue to present significant unanswered questions and exciting avenues for future investigation.

Moving forward, the research community is poised to delve deeper into the nuanced biophysical interactions of SS-31, exploring novel physiological and pathophysiological models, and integrating cutting-edge ‘omics technologies for a more comprehensive understanding. This next generation of SS-31 research will aim to refine our understanding of its cellular and molecular actions, optimize its research application, and uncover previously unrecognized facets of mitochondrial modulation. Such investigations are crucial for fully characterizing SS-31’s attributes and expanding its utility as a research tool in the study of cellular aging and mitochondrial dysfunction.

This section outlines several key directions where SS-31 research is expected to evolve, from dissecting more intricate mechanistic details to exploring its potential in new experimental systems and employing advanced analytical methodologies. These future studies will not only solidify our knowledge base but also open doors for innovative approaches in mitochondrial health research, leveraging SS-31’s unique properties as a targeted research agent.

Expanding Mechanistic Elucidation and Biophysical Interactions

While the interaction of SS-31 with cardiolipin on the inner mitochondrial membrane is a well-documented cornerstone of its mechanism, future research endeavors are directed towards a more granular understanding of this interaction. Investigators are keen to determine if SS-31 exhibits specificity for particular cardiolipin species or membrane microdomains, and how this binding precisely alters membrane biophysics beyond general cardiolipin remodeling. Questions remain regarding the kinetic aspects of SS-31 binding and dissociation, and whether these dynamics are influenced by specific mitochondrial states, such as membrane potential or lipid peroxidation levels. Understanding these subtleties could reveal new regulatory layers governing SS-31’s efficacy in different cellular environments.

Further exploration is also warranted regarding the precise impact of SS-31 on the function of cardiolipin-associated proteins, particularly those integral to the electron transport chain (ETC) and ATP synthase. While its positive effects on bioenergetics are recognized, the direct or indirect modulation of individual ETC complexes or supercomplexes via cardiolipin binding needs more specific dissection. This could involve advanced spectroscopic techniques and structural biology approaches to visualize and quantify changes in protein conformation or activity in the presence of SS-31. Additionally, researchers are investigating whether SS-31’s influence extends to other mitochondrial membrane proteins or transport systems, suggesting a broader role in overall mitochondrial membrane integrity and function.

Another crucial area involves a more thorough mapping of SS-31’s effects on mitochondrial dynamics and quality control pathways. While studies have shown its influence on fission, fusion, and mitophagy, the precise molecular triggers and signaling pathways downstream of SS-31 that mediate these effects remain to be fully elucidated. For instance, does SS-31 directly interact with components of the fission/fusion machinery, or are its effects mediated indirectly through improvements in mitochondrial energetic status? Similarly, unraveling how SS-31 might prime mitochondria for more efficient mitophagy, or modulate specific mitophagy receptors, represents a significant future research direction. Such insights could reveal novel targets for mitochondrial quality control regulation.

Exploring Novel Research Models and Physiological Contexts

The utility of SS-31 as a research tool extends far beyond its current primary applications. Future studies are poised to investigate its role in a broader spectrum of cellular and physiological models of aging and disease. For instance, its impact on distinct immune cell populations, where mitochondrial health dictates immune competence and inflammatory responses, represents an emerging area. Understanding how SS-31 modulates mitochondrial function in macrophages, T cells, or glial cells could offer new perspectives on chronic inflammation and neuroinflammation in various preclinical paradigms. This includes exploring its potential to modulate the immunometabolism of these cells, influencing their differentiation and effector functions.

Furthermore, the investigation of SS-31 in models of rare mitochondrial disorders, where specific genetic defects lead to profound bioenergetic dysfunction, could provide unique insights into its mechanism of action. By studying SS-31 in these defined genetic contexts, researchers may uncover specific pathways that are particularly responsive or resistant to its effects. Similarly, exploring its impact on stem cell biology—including induced pluripotent stem cells (iPSCs) and tissue-specific stem cell niches—could shed light on how mitochondrial quality influences cell fate, self-renewal, and differentiation capacity. These studies are critical for understanding fundamental biological processes where mitochondrial integrity is paramount.

Another promising direction involves detailed research into SS-31’s influence on specific organelle crosstalk. Mitochondria do not operate in isolation but interact extensively with other organelles like the endoplasmic reticulum (ER) and lysosomes. Future research can explore how SS-31-mediated mitochondrial improvements might consequently impact ER stress, calcium homeostasis, or lysosomal function, thereby influencing broader cellular health and stress responses. Investigating these complex inter-organelle communications in various stress models could reveal novel networks impacted by SS-31, providing a more holistic view of its cellular effects.

Advancing Methodological Approaches and ‘Omics Integration

The future of SS-31 research will heavily rely on the integration of advanced methodologies and multi-omics approaches to provide unprecedented resolution and breadth of understanding. Single-cell ‘omics technologies, such as single-cell RNA sequencing and single-cell metabolomics, will be instrumental in dissecting heterogeneous cellular responses to SS-31 within complex tissues or mixed cell populations. This will allow researchers to move beyond bulk average measurements and identify specific cell types or states that are most responsive to mitochondrial modulation, thereby refining research hypotheses and experimental design. For ensuring the reliability of such advanced studies, robust quality testing of research materials is paramount.

High-resolution imaging techniques, including super-resolution microscopy and cryo-electron tomography, offer the capacity to visualize SS-31’s localization and its impact on mitochondrial ultrastructure with nanometer precision. Such approaches can reveal subtle changes in inner mitochondrial membrane morphology, cristae organization, or membrane-protein interactions that are directly influenced by SS-31 binding. Coupling these imaging modalities with advanced computational modeling could generate dynamic simulations of SS-31’s interaction with cardiolipin and its subsequent effects on mitochondrial function, providing a powerful predictive tool for future experimental design.

Comprehensive metabolomics and lipidomics analyses are also poised to play a critical role. By profiling the entire cellular metabolome and lipidome, researchers can identify subtle shifts in metabolic fluxes and lipid species, particularly cardiolipin and related phospholipids, in response to SS-31. This can provide a detailed ‘fingerprint’ of SS-31’s metabolic impact, allowing for the identification of novel downstream pathways or compensatory mechanisms. Furthermore, combining these omics data with proteomic and epigenomic analyses will enable a systems-level understanding of how SS-31 influences gene expression, protein abundance, and post-translational modifications that collectively govern mitochondrial and cellular health.

Investigating Pharmacological Nuances and Combinatorial Strategies

A deeper understanding of SS-31’s pharmacokinetic and pharmacodynamic properties in various research models remains a vital area of future inquiry. This includes more precise studies on its biodistribution across different tissues and cell types, its cellular uptake mechanisms, and its intracellular stability. Investigating the influence of different delivery methods on these parameters can help optimize experimental protocols for specific research goals. For instance, exploring novel encapsulation or targeting strategies in preclinical models could enhance its bioavailability to specific mitochondrial populations within challenging tissues, such as the brain.

Furthermore, researchers are increasingly interested in exploring combinatorial research strategies, investigating the synergistic or additive effects of SS-31 when co-administered with other mitochondrial modulators or cellular stressors. This could involve combining SS-31 with NAD+ precursors, sirtuin activators, autophagy-inducing compounds, or specific antioxidants to determine if combined approaches yield enhanced or distinct mitochondrial benefits in various research models. Such studies could uncover complex interplay between different pathways influencing mitochondrial health and potentially identify novel research hypotheses for multifaceted interventions. A foundational understanding of the mechanism of action of SS-31 is essential for designing rational combinatorial studies.

Finally, rigorous dose-response and time-course studies are imperative to fully characterize SS-31’s effects. While initial studies have established effective concentrations and durations, future research will aim to fine-tune these parameters across a broader range of experimental conditions and cellular contexts. This includes investigating the long-term impact of sustained SS-31 exposure on mitochondrial adaptation and resilience in chronic stress models, as well as understanding potential differences in responsiveness across various cell lines, primary cells, and tissues. Such detailed characterization is crucial for maximizing the utility and reproducibility of SS-31 in future research endeavors.

Key Research Questions for Future SS-31 Investigations

As the field of mitochondrial research continues to advance, several specific questions stand out as critical for further illuminating the role and potential of SS-31. These inquiries will drive the next generation of studies, pushing the boundaries of our understanding of this unique peptide and mitochondrial biology:

What are the precise structural changes induced by SS-31 binding to different cardiolipin species, and how do these changes impact the function and organization of specific inner mitochondrial membrane protein complexes?
How does SS-31 selectively target and influence mitochondrial sub-populations within a single cell or tissue, such as subsarcolemmal versus intermyofibrillar mitochondria in muscle tissue research models?
Can SS-31 modulate specific epigenetic markers or transcription factors that directly regulate mitochondrial biogenesis, dynamics, or cellular stress response pathways, independent of its immediate bioenergetic effects?
What is the long-term adaptive response of the mitochondrial proteome and lipidome to chronic SS-31 exposure in models of persistent metabolic or oxidative stress?
Does SS-31 influence the communication between mitochondria and other organelles, such as the endoplasmic reticulum or peroxisomes, and how do these interactions contribute to its overall cellular effects?
What novel combinatorial research strategies, involving SS-31 and other mitochondrial-modulating compounds, could reveal synergistic effects on mitochondrial resilience and cellular longevity in various preclinical research models?
How can advanced imaging and single-cell ‘omics technologies be best leveraged to provide a spatially and temporally resolved understanding of SS-31’s cellular and molecular mechanisms?

Frequently Asked Questions

What is SS-31?

SS-31, also identified by its research alias Elamipretide, is a synthetic mitochondria-targeted tetrapeptide. It is a subject of extensive investigation in cellular bioenergetics and mitochondrial function research, owing to its specific targeting mechanism.

Q: What is the primary mechanism of action of SS-31 under research investigation?

A: As a mitochondria-targeted tetrapeptide, SS-31 is studied for its ability to interact with cardiolipin within the inner mitochondrial membrane. This interaction is a central focus of research regarding its observed influence on mitochondrial bioenergetics and cellular energy metabolism in various experimental models.

Q: How many research publications are available concerning SS-31?

A: As of the latest review, SS-31 is featured in approximately 122 indexed publications on PubMed, reflecting a substantial body of research exploring its biological effects and mechanisms at the cellular and subcellular levels.

Q: Has SS-31 been investigated in clinical research settings?

A: Yes, SS-31 has been the subject of at least one registered study listed on ClinicalTrials.gov, indicating its progression into investigative research phases to characterize its biological activity and characteristics in various contexts.

Q: What are the key areas of research where SS-31 is commonly studied?

A: Researchers commonly investigate SS-31 in studies related to mitochondrial function, cellular bioenergetics, oxidative stress modulation, and its role in maintaining cardiolipin integrity within the mitochondrial membrane.

Q: What is the chemical classification of SS-31?

A: SS-31 is classified as a mitochondrial-targeted peptide, specifically a tetrapeptide. Its structural design directs it to mitochondria, enabling researchers to explore its localized effects.

Q: Are there any other names or aliases for SS-31 used in research?

A: Yes, in research literature and databases, SS-31 is frequently referred to by its alias, Elamipretide.

Q: What kind of cellular components does SS-31 interact with, according to research?

A: Research indicates that SS-31 primarily interacts with cardiolipin, a unique phospholipid found in the inner mitochondrial membrane. This interaction is hypothesized to be fundamental to its observed effects on mitochondrial function and bioenergetics.

Scientific References

All information from Royal Peptide Labs is provided for in-vitro laboratory and research use only — not for human, veterinary, diagnostic, or therapeutic use.